BD2 Commits Over $13 Million to Decode Mood Switching in Bipolar Disorder

Breakthrough Discoveries for thriving with Bipolar Disorder, the independent nonprofit known as BD², has announced its fourth round of Discovery Research grants, committing more than $13 million to one of the most perplexing questions in psychiatry: what actually happens in the brain when a person with bipolar disorder suddenly flips from depression into mania, or the reverse? The new funding will support three research teams based at Harvard Medical School, Johns Hopkins University, and Stanford University, each of which will receive $4.5 million over three years. The teams join an existing portfolio of BD²-funded investigators working to unravel the biology of a condition that affects nearly 3 percent of the global population and remains one of the most burdensome and poorly understood psychiatric illnesses worldwide.

The scientific target of the new grants is mood state switching, the abrupt transition between opposing emotional states that defines bipolar disorder. For the vast majority of people living with the condition, these sudden shifts are not gradual mood changes but dramatic reversals that can upend sleep, energy, judgment, and behavior within days or even hours. Despite decades of clinical observation, the biological mechanisms that drive these switches remain largely unknown, as does the question of why certain external stressors—substance use, disrupted light exposure, seasonal change—reliably seem to precipitate episodes in vulnerable individuals. The three newly funded teams will each attack this problem from a distinct biological angle, and their combined results are intended to build a complementary picture of what tips the bipolar brain from one state into another.

At Stanford University, a team led by Laramie Duncan, PhD, will pursue a striking recent discovery: a rare neuron type located in the retrosplenial cortex, a brain region that has received comparatively little attention in psychiatric research, appears to be strongly linked to bipolar disorder. The retrosplenial cortex sits at the intersection of memory, spatial navigation, and internally directed thought, making it a plausible hub for the self-referential distortions that characterize both depressive and manic states. Duncan’s team will now investigate how this specific cell type contributes to mood switching, combining genetic analysis with neuroimaging to assess whether changes in retrosplenial cortex connectivity track the onset of episodes. The project will also draw on BD²’s longitudinal cohort of more than 600 people with bipolar disorder to test a clinically ambitious idea: whether an individual’s genetic risk profile can help predict which treatments are most likely to work, moving the field closer to genetically informed treatment matching.

The Harvard Medical School team, led by Susan Dymecki, MD, PhD, is focused on a circuit-level mechanism that connects the body’s master circadian clock to mood and arousal centers in the brain. Dymecki’s group recently identified a neural pathway that shifts its signaling in response to changes in light exposure, and this discovery is directly relevant to one of bipolar disorder’s most consistent clinical observations: patients are exquisitely sensitive to changes in day length, jet lag, and nighttime screen exposure, all of which are well-documented triggers for mood-switch episodes. The team will now test the hypothesis that dysfunction in this light-responsive circuit is what converts an ordinary change in illumination into a pathological mood episode, and whether the circuit can be safely targeted to stabilize mood. If successful, the work could open a fundamentally new therapeutic avenue grounded in the brain’s timing machinery rather than in traditional neurotransmitter systems.

At Johns Hopkins University, Akira Sawa, MD, will lead a team examining the problem at the level of individual neurons, focusing on potassium and calcium channels—the molecular gates that control electrical signaling in the brain. These channels are critical to neural activity, and the team will study how they interact and how abnormal changes in that interaction may disrupt signaling in ways that drive mood switching. The experimental strategy is unusually broad for a single grant, combining cell-based models, animal studies, and human primary neurons derived from nasal biopsy tissue, an approach that gives researchers access to living human neurons without invasive brain surgery. Crucially, the team will also use data from the first data release of BD²’s longitudinal cohort, testing whether the channel mechanism they identify in the laboratory holds up as both a potential treatment target and a biomarker usable for diagnosis in real patients.

Two of the three new teams will maintain formal collaborations with the BD² Integrated Network, the organization’s longitudinal cohort study designed to accelerate findings and connect laboratory discoveries to real-world clinical settings. This structure reflects a deliberate design philosophy: rather than allowing basic science and clinical research to proceed on separate tracks, BD² requires its grantees to build data-sharing pipelines so that molecular and circuit-level findings can be tested against the lived experience of hundreds of patients followed over time. For a condition as variable and episodic as bipolar disorder, this kind of longitudinal infrastructure is considered essential, because single snapshots of brain state cannot capture the dynamic transitions that are the disorder’s defining feature.

“Understanding why and how mood states switch is essential to developing more precise, effective treatments, and we’re proud to support this work as part of our long-term commitment to helping people with bipolar disorder lead thriving lives,” said Daniel Pham, PhD, Head of Science and Innovation at BD². The statement underscores the organization’s framing of the grants not as incremental funding but as part of a long-haul effort to move bipolar disorder research from descriptive psychiatry toward mechanistic biology, where interventions can be matched to the specific processes malfunctioning in each patient.

With the new awards, BD² has now committed more than $119 million to bipolar disorder research since its founding, spanning genetics platforms, brain omics, and clinical cohort infrastructure. The fourth round of Discovery Research builds on earlier grantee cohorts that have examined the genetic risk factors of the illness, the molecular and circuit-level mechanisms underlying sleep disruption, and the mechanisms of action of existing drug-based therapies. Taken together, these strands form an increasingly interconnected portfolio: genetic risk informs who is vulnerable, circadian and sleep biology explains some environmental triggers, and the new grants probe the switch mechanisms themselves. The open-science model, in which data, methods, and resources are shared across initiatives, is intended to shorten the time between scientific breakthrough and meaningful clinical impact for the tens of millions of people affected globally.

Alongside the new awards, BD² has opened a fifth round of Discovery Research funding, inviting teams to apply for grants of up to $5 million over four years—a notable expansion from previous cycles, which offered $4.5 million over three years. The extended duration and larger budget are designed to give successful teams more time and resources to increase their scientific impact, a response to what the organization describes as the community’s need for greater funding and long-term stability in a field that has historically been under-resourced relative to the global burden of the illness. The new request for applications also places a spotlight on women’s health and sex differences in bipolar disorder, an area of growing urgency given mounting evidence that disease course, episode patterns, and treatment responses can differ substantially between women and men, particularly across reproductive life stages. Applications must include connections into the Integrated Network, ensuring that the next generation of BD²-funded studies remains tethered to patient data and real-world outcomes.

For researchers and clinicians watching the field, the significance of the new grants lies less in any single experiment than in the convergence of scales: a rare cell type in an overlooked cortical region, a light-sensitive circuit linking circadian timing to arousal, and ion channels governing neuronal excitability are all being interrogated as candidate mechanisms for the same phenomenon. If even one of these lines of investigation identifies a druggable target or a usable biomarker, the path from laboratory insight to stabilized mood could shorten considerably. In the meantime, the expansion of funding and the explicit focus on sex differences signal that bipolar disorder research is entering a phase in which the field’s biggest questions—why moods flip, and how to predict and prevent the flip—are finally being addressed with the tools, cohorts, and resources their complexity demands.

Subject of Research: Biological mechanisms of mood state switching in bipolar disorder

Article Title: BD² awards over $13 million in grants to understand the mechanisms of mood state switching in bipolar disorder and announces new funding available

Article References: BD² awards over $13 million in grants to understand the mechanisms of mood state switching in bipolar disorder and announces new funding available. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bipolar disorder, mood state switching, BD2 grants, discovery research, circadian rhythm, retrosplenial cortex, ion channels, women's health, longitudinal cohort, neural circuits, biomarkers, mental health funding